AAC
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Takác, M.
Right arrow Articles by Bläsi, U.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Takác, M.
Right arrow Articles by Bläsi, U.
Antimicrobial Agents and Chemotherapy, July 2005, p. 2934-2940, Vol. 49, No. 7
0066-4804/05/$08.00+0     doi:10.1128/AAC.49.7.2934-2940.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.

Phage P68 Virion-Associated Protein 17 Displays Activity against Clinical Isolates of Staphylococcus aureus

Marian Takác and Udo Bläsi*

Max F. Perutz Laboratories, Department of Microbiology and Immunobiology, University Departments at the Vienna Biocenter, Dr. Bohrgasse 9/4, 1030 Vienna, Austria

Received 27 July 2004/ Returned for modification 26 January 2005/ Accepted 27 March 2005

Phage-encoded murein hydrolases are either part of the lysis cassette or found as structural components of the phage virion. Here, we show that Staphylococcus aureus bacteriophage P68 contains a virion-associated muralytic enzyme. Protein 17 has a composite structure. The N-terminal part comprises the muralytic activity, whereas the C-terminal part is required for binding to the cell surface. A high multiplicity of infection with phage P68 caused rapid lysis, and purified protein 17 triggered premature lysis when added to S. aureus cells prior to infection with P68, suggesting that it functions to weaken the murein at the site of phage DNA entry. Protein 17 displayed activity against clinical S. aureus isolates, which are resistant to infection by phage P68, demonstrating that the protein targets surface structures distinct from the phage receptor. This broad activity spectrum of protein 17 could qualify virion-associated muralytic enzymes as attractive antimicrobials.


* Corresponding author. Mailing address: Max F. Perutz Laboratories, Department of Microbiology and Immunobiology, University Departments at the Vienna Biocenter, Dr. Bohrgasse 9/4, 1030 Vienna, Austria. Phone: 43 1 4277 54609. Fax: 43 1 4277 9546. E-mail: udo.blaesi{at}univie.ac.at.


Antimicrobial Agents and Chemotherapy, July 2005, p. 2934-2940, Vol. 49, No. 7
0066-4804/05/$08.00+0     doi:10.1128/AAC.49.7.2934-2940.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.







Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Clin. Vaccine Immunol. Clin. Microbiol. Rev.
J. Clin. Microbiol. ALL ASM JOURNALS

Copyright © 2005 by the American Society for Microbiology. All rights reserved.